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Abstract
Background: In the placebo-controlled trial ACTG A5197, a trend favoring viral suppression was seen in the HIV-1-infected
subjects who received a recombinant Ad5 HIV-1 gag vaccine.
Objective: To identify individuals with initial viral suppression (plasma HIV-1 RNA set point,3.0 log10 copies/ml) during the
analytic treatment interruption (ATI) and evaluate the durability and correlates of virologic control and characteristics of HIV
sequence evolution.
Methods: HIV-1 gag and pol RNA were amplified and sequenced from plasma obtained during the ATI. Immune responses
were measured by flow cytometric analysis and intracellular cytokine expression assays. Characteristics of those with and
without initial viral suppression were compared using the Wilcoxon rank sum and Fisher’s exact tests.
Results: Eleven out of 104 participants (10.6%) were classified as initial virologic suppressors, nine of whom had received the
vaccine. Initial virologic suppressors had significantly less CD4+ cell decline by ATI week 16 as compared to non-suppressors
(median 7 CD4+ cell gain vs. 247 CD4+ cell loss, P = 0.04). However, of the ten initial virologic suppressors with a pVL at ATI
week 49, only three maintained pVL ,3.0 log10 copies/ml. HIV-1 Gag-specific CD4+ interferon-c responses were not
associated with initial virologic suppression and no evidence of vaccine-driven HIV sequence evolution was detected.
Participants with initial virologic suppression were found to have a lower percentage of CD4+ CTLA-4+ cells prior to
treatment interruption, but a greater proportion of HIV-1 Gag-reactive CD4+ TNF-a+ cells expressing either CTLA-4 or PD-1.
Conclusions: Among individuals participating in a rAd5 therapeutic HIV-1 gag vaccine trial, initial viral suppression was
found in a subset of patients, but this response was not sustained. The association between CTLA-4 and PD-1 expression on
CD4+ T cells and virologic outcome warrants further study in trials of other therapeutic vaccines in development.
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Introduction
The initial optimism that antiretroviral therapy (ART) could lead
to the eradication of HIV infection has been tempered by the
realization that virologic control is lost with the discontinuation of
ART even after an extended period on treatment [1]. Despite
improved tolerability of newer ART regimens, long-term treatment
carries risks of drug resistance, metabolic, and other complications
of chronic ART use [2], and is constrained by limited access in
resource-poor regions. Therefore, achieving drug-free remission has
become a major focus of research in HIV therapeutics [1,3,4].
Therapeutic HIV-1 vaccines directed to the cell-mediated immune
system could boost HIV-specific immune responses and improve
virologic control in the absence of ART [5].
AIDS Clinical Trials Group (ACTG) protocol A5197 was a
randomized, placebo-controlled trial to test the effect of a
recombinant adenovirus serotype 5 (rAd5) HIV-1 gag therapeutic
vaccine on plasma viral load (pVL) in subjects undergoing an
analytic treatment interruption (ATI) [6]. A total of 110
participants underwent a 16-week ATI after randomization in a
2:1 ratio to receive either three doses of vaccine or placebo. The
vaccine induced significant CD4+ and CD8+ HIV-1 Gag-specific
T-cell responses in a subset of participants and marginally
significant decreases in the level of viremia during the analytic
treatment interruption. Vaccination was associated with lower
ATI viral load even after controlling for viral and host genetic
factors [7]. In addition, the magnitude of detectable HIV-1 Gag-
specific CD4+ IFN-c-producing cells was negatively correlated
with viral load set point [6].
The goals of this analysis were to characterize study participants
with initial virologic suppression, evaluate viral and immunologic
correlates of such a response, and determine the durability of
virologic control 49 weeks after treatment interruption.
Methods
Patients and Study Design
Study design and patient inclusion criteria for ACTG A5197
have been described in detail [6]. Eligible participants were on
ART with CD4+ cell counts $500/mm3, plasma HIV-1 RNA
levels of #50 copies/mL at screening with a history of pVL #500
copies/mL for 24 months prior to enrollment. Participants
received a rAd5 vaccine containing an HIV-1 gag insert or
placebo at weeks 0, 4, and 26 (Step I). Starting at week 39, 110
participants (N= 73 vaccine, N= 37 placebo) with CD4+ cell
counts $500/mm3 and no confirmed viral rebound in Step I (two
consecutive pVL.500 copies/mL) underwent a 16 week ATI
(Step II). The pVL set point acted as one of the primary endpoints
and was defined as the mean of the ATI weeks 12 and 16 pVL (on
the log10 scale). After ATI week 16, study participants had the
option of resuming ART or continuing the treatment interruption.
Resumption of ART was recommended under any of the
following conditions: confirmed CD4+ cell count ,300/mm3,
three consecutive HIV-1 RNA levels $300,000 copies/mL,
AIDS-defining illness, or development of retroviral rebound
syndrome, clinically significant Immunosuppression, based on
subject’s clinician preference, or pregnancy. Participants with an
HIV-1 set point of ,3.0 log10 copies/ml soon after ATI were
categorized as early virologic suppressors. This level of plasma
viremia has been used to define virologic suppression on ART [8–
10] and transient episodes of low-level viremia (‘‘blips’’) [11,12].
Each individual’s time on ART was calculated as the interval
between the date of first ART initiation and date of treatment
interruption.
HLA Typing
HLA class I typing was performed following the sequence-specific
oligonucleotide probing and sequence-based typing protocols
recommended by the 13th International Histocompatibility Work-
shop (http://www.ihwg.org). Protective HLA alleles were defined a
priori as HLA B*13, B*27, B*51, B*57, and B*5801. Unfavorable
HLA alleles were defined as the HLA-B*35-Px variants (B*3502,
3503, 3504, or 5301) [13]. The protective HLA group includes all
individuals with at least one protective HLA allele. Those without a
protective HLA allele, but with at least one unfavorable HLA allele
were categorized in the unfavorable HLA group. Participants with
neither protective nor unfavorable HLA alleles were categorized in
the neutral HLA group.
Intracellular Cytokine Staining Assays (ICS) and Flow
Cytometric Analysis
Cell-mediated immune responses at study weeks 0, 8, and 38
were evaluated by an intracellular cytokine staining assay for
interferon-gamma (IFN-c), tumor necrosis factor-alpha (TNF-a),
and interleukin-2 (IL-2) as previously described [6,14,15].
Peripheral blood lymphocytes were first exposed to a Gag
peptide pool for 18 hours. CD4+ and CD8+ T cells producing
cytokines and expressing cytotoxic T lymphocyte antigen 4
(CTLA-4) or programmed death-1 (PD-1) were detected by
multiparameter flow cytometry. A ‘‘positive change’’ in the
numbers of CD4+ or CD8+ IFN-c-producing T cells in response
to Gag stimulation was defined as at least a two-fold increase
from baseline to week 38.
Viral sequencing fromPlasma and Sequence Analysis. Most
participants had plasma viral sequences analyzed at three time points: at
the time of initial detectable viremia (in general, ATI weeks 2–7), ATI
week 16 (study week 54), and ATI week 49 (study week 87). The Gag
and reverse transcriptase (RT) coding sequences were amplified from
plasma HIV-1 RNA by nested RT-PCR using gene-specific primers.
Population (‘‘bulk’’) sequencing was performed on an ABI 3730
automated DNA sequencer. Chromatograms were analyzed using
Sequencher (Genecodes). We calculated the number of amino acid
mismatches between the vaccine or consensus HIV-1 subtype B
sequence and the patient-derived sequence. HLA-associated
polymorphisms in patient HIV-1 sequences were determined based
on a published list [16].
Statistical Analysis. A comparison of host genetic, im-
munologic, and viral sequence characteristics of those with and
without initial viral suppression was performed using the 2-sample
Wilcoxon rank sum test. Fisher’s exact tests were used to compare
dichotomous outcomes between initial viral suppressors and the
non-suppressors. All of the p-values are exact 2-sided p-values. No
adjustments were performed for multiple comparisons. Note that
the comparisons presented here were not originally planned in the
protocol.
Results
Characteristics of Initial Virologic Suppressors
Of the 104 participants with evaluable pVL set point, 11 were
found to have a pVL set point ,3.0 log10 copies/ml and were
categorized as an initial virologic suppressors (Table 1). Eighty-two
percent (9/11) of initial virologic suppressors received the vaccine
as compared to 66% (61/93) of the non-suppressors (P=0.5).
Initial virologic suppressors had a median pVL set point of 2.6
log10 RNA copies/ml versus a pVL set point of 4.2 log10 RNA
copies/ml for virologic non-suppressors. The time on ART and
distribution of HLA allele groups (protective, neutral, unfavorable)
was not significantly different between the initial virologic
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suppressor and non-suppressor groups. When compared to CD4+
cell counts at study entry, participants with initial virologic
suppression had a median gain of 7 CD4+ cells/mm3 at ATI week
16. This was in contrast to a median loss of 247 CD4+ cells/mm3
among non-suppressors (P=0.04).
Initial Virologic Suppression and Immune Preservation
was not Sustained
Of the 10 participants with initial virologic suppression and a
measured pVL at ATI week 49 off of ART, only 3 subjects
continued to have a pVL,3.0 log10 copies/ml (Table 2, Figure 1).
Two of the individuals with sustained virologic control had
protective HLA alleles: One participant was found to have HLA
B*27 and B*57, while another had B*27. For participants with
initial virologic suppression, the median CD4+ cell decline
between ATI weeks 16 and 49 was 82 cells/mm3 (N= 9) as
compared to a decline of 99 cells/mm3 for initial non-suppressors
(N= 52, P=0.4).
Virologic Factors Associated with Initial Virologic
Suppression
Of those with available pre-ART pVL data, individuals with
initial virologic suppression had lower pre-ART pVL, but this
difference was of marginal statistical significance (median 3.9
[N= 8] versus 4.8 [N= 62] log10 HIV-1 copies/ml, respectively,
P=0.07). In addition, those with initial virologic suppression had a
significantly greater decrease between pre-ART pVL and the set
point pVL compared to those without initial virologic suppression
(median decrease 1.2 versus 0.64 log10 HIV-1 copies/ml,
respectively, P=0.006). Almost all individuals were found to have
HLA-associated polymorphisms in HIV-1 Gag early in the
treatment interruption with a median of four polymorphisms per
person. In the eight individuals with plasma available at ATI week
49, four were found to have accumulated additional Gag escape
mutations (median 1.5 mutations). No significant differences were
seen in the proportion of Gag polymorphisms between initial
virologic suppressors and non-suppressors at either the first
Table 1. Baseline characteristics of the participants.
Variable Overall Initial virologic suppressors
Initial non-
suppressors P-valuesa
(N = 104) (N = 11) (N = 93)
Age, median, years 42 40 42 0.18
Male, % of subjects (N) 95 (99) 100 (11) 95 (88) 1.00
Treatment arm, % of subjects (N) 0.50
Vaccine 67 (70) 82 (9) 66 (61)
Placebo 33 (34) 18 (2) 34 (32)
Race, % of subjects (N) 0.59
White 69 (72) 73 (8) 69 (64)
Black(non-Hispanic) 9 (9) 18 (2) 8 (7)
Hispanic 16 (17) 9 (1) 17 (16)
.1 race 1 (1) 0 (0) 1 (1)
Asian, Pacific Islander 5 (5) 0 (0) 5 (5)
Baseline CD4+ cell count,
median [IQR], cells/mm3
817
[712–1069]
825
[767–972]
816
[707–1096]
0.96
Pre-ART HIV-1 RNA,
median [N, IQR], copies/mL
4.7
[70, 4.3–5.1]
3.9
[8, 3.5–5.0]
4.8
[62, 4.3–5.1]
0.07
HLA group, % of subjects (N)b 0.56
Protective 35 (36) 27 (3) 36 (33)
Neutral 59 (62) 64 (7) 59 (55)
Unfavorable 6 (6) 9 (1) 5 (5)
Time on ART, median [IQR], yrs 6.2
[3.8–9.1]
6.8
[3.3–8.1]
6.2
[4.0–9.2]
0.59
ART Regimen, % of subjects (N)c
NNRTI, no PI 50 (52) 55 (6) 49 (46)
PI, no NNRTI 34 (35) 18 (2) 36 (33)
PI and NNRTI 5 (5) 0 (0) 5 (5)
Other 11 (12) 27 (3) 10 (9) 0.30
Data are percent (no.) of patients unless otherwise indicated.
aP-values compare the distribution of baseline characteristics between initial virologic suppressors and non-suppressors. For continuous variable, Wilcoxon rank sum
test was used, for categorical variable, Fisher’s exact test was use. All the p-values are exact 2-sided p-values.
bHLA type defined based on the presence of protective HLA alleles (B*13, B*27, B*51, B*57, and B*5801), unfavorable (B*35-Px variants: B*3502, 3503, 3504, or 5301), or
neutral HLA alleles (all others).
cAntiretroviral regimen at the time of study entry.
doi:10.1371/journal.pone.0034134.t001
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available ATI time point (median 0.44 versus 0.45, respectively,
P=0.4) or at ATI week 49 (median 0.48 versus 0.47, respectively,
P=0.9). This finding suggests that the lack of sustained pVL
suppression in the latter group could not be explained by the
accumulation of HLA-associated escape mutations in Gag.
The number of predicted amino acid mismatches was calculated
between the vaccine gag sequence and the earliest available
patient-derived HIV-1 sequence after ATI (median 4 weeks).
These early sequences represent viral populations least likely to
have been shaped by significant vaccine-driven immune responses.
There was no significant difference in the number of Gag amino
acid mismatches between the vaccine and patient HIV-1
sequences among initial virologic suppressors and non-suppressors
who received the vaccine (median 33 versus 29 amino acid
mismatches, respectively, P=0.19). The change in the number of
vaccine-to-patient Gag amino acid mismatches between the first
ATI time point and ATI week 49 was used as a potential reflection
of vaccine-induced viral evolution. However, we detected little
overall change in the number of mismatched amino acids between
the two time points and no significant differences between initial
virologic suppressors and non-suppressors (mean 0 vs. 0.24 amino
acid changes, respectively, P=0.59).
Immunologic Factors Associated with Initial Virologic
Suppression
There was no significant difference between initial virologic
suppressors and non-suppressors in the CD4+ T-cell count at
study entry (median 846 versus 839 cells/mm3, P=0.58). In the
initial A5197 analysis, an inverse association was seen between the
ATI set point viral load and the number of HIV-1 Gag-specific
CD4+ IFN-c-producing CD4+ T cells at study weeks 8 and 38 [6].
Table 2. Characteristics of initial viral suppressors.
PID Study Arm HLA group Pre-ARV RNA copies/ml (log10) ATI Set Point RNA copies/ml (log10) ATI week 49 RNA copies/ml (log10)
1 Vaccine Protective 3.3 2.9 2.7
2 Vaccine Protective 2.4 4.8
3 Vaccine Protective 5.1 2.7 2.6
4 Vaccine Neutral 3.7 2.4 3.5
5 Vaccine Neutral 1.7 1.7
6 Vaccine Neutral 4.0 2.9 3.9
7 Vaccine Neutral 3.8 2.6 3.6
8 Vaccine Neutral 4.8 2.99 3.7
9 Vaccine Unfavorable 2.8 4.1
10 Placebo Neutral 5.7 2.1 4.8
11 Placebo Neutral 2.6 1.7
PID, patient identification number.
doi:10.1371/journal.pone.0034134.t002
Figure 1. Viral load trends for individuals with ATI set point viral load ,3.0 log10 copies/ml. The light yellow highlighted region
encompass the HIV-1 viral load measurements used to calculate the viral set point (mean of the ATI weeks 12 and 16 HIV-1 RNA copies/ml). Pre-ARV,
pre-antiretroviral therapy; PID, patient identification number.
doi:10.1371/journal.pone.0034134.g001
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There were no significant differences between initial virologic
suppressors and non-suppressors in the number of HIV-1 Gag-
specific IFN-c-producing CD4+ T-cells at week 8 or 38 (week 8
median 2.4 versus 2.2 log10 cells/10
6 lymphocytes, P=0.21; week
38 median 2.5 versus 2.2 log10 cells/10
6 lymphocytes, P=0.20), or
Gag-specific IFN-c-producing CD8+ T-cells (week 8 median 2.8
versus 2.9 log10 cells/10
6 lymphocytes, P=0.35; week 38 median
2.9 versus 2.9 log10 cells/10
6 lymphocytes, P=0.55). Similarly, no
significant differences were detected between initial virologic
suppressors and non-suppressors in the number of subjects who
had an increase in HIV-1 Gag-specific IFN-c-producing CD4+
and CD8+ T-cells from study entry to week 38. Thirty percent (3/
10) of initial virologic suppressors had a significant increase in the
number of CD4+ IFN-c-producing cells between baseline and
week 38 as compared with 35% (31/89) non-suppressors (P=1.0).
Fifty percent (5/10) of initial virologic suppressors had a significant
increase in the number of CD8+ IFN-c-producing cells as
compared with 38% (34/89) of non-suppressors (P=0.51).
The number of HIV-1 Gag-specific CD4+ IFN-c-producing
cells detected was associated with vaccination status, but not with
status of initial virologic suppression. There were no differences in
the magnitude of HIV-1 Gag-specific CD4+ IFN-c-producing
cells between vaccinated participants with or without initial
virologic suppression (median 2.4 versus 2.3 log10 cells/10
6
lymphocytes, P=0.68 at week 8, and median 2.5 versus 2.3
log10 cells/10
6 lymphocytes, P=0.15 at week 38, Figure 2). In
addition, vaccinated participants regardless of status of initial
virologic suppression were found to have higher levels of HIV-1
Gag-specific IFN-c-producing cells at week 8 compared to initial
non-suppressors who had received placebo (Figure 2). These
results indicate that the magnitude of in vitro CD4+ IFN-c
responses to HIV-1 Gag peptides may have been influenced by
therapeutic vaccination, but was not clearly correlated with initial
virologic suppression.
The association of initial virologic suppression with expression
of the immunomodulatory molecules CTLA-4 and PD-1 on CD4+
and CD8+ cells expressing either TNF-a, IFN-c, or IL-2 were
evaluated in a subset of participants at both study entry and study
week 38. At week 38, participants with initial virologic suppression
had significantly lower proportions of CD4+ T cells expressing
CTLA-4 (median 8.9% [N=6] versus 14.1% [N=46], P=0.02,
Figure 3). No significant differences were seen in the expression of
CD4+ PD-1+ T cells between those with and without initial
virologic suppression (median 10.4% [N=6] versus 9.1%
[N=46], P=0.67). However, participants with initial virologic
suppression had a significantly higher percentage of Gag-specific
CD4+ TNF-a+ cells expressing either CTLA-4 or PD-1 (median
CTLA-4 expression 54% [N=5] for initial suppressors versus
33% [N=44] for non-suppressors, P=0.01; and median PD-1
expression 36% [N=5] for suppressors versus 14% [N=44] for
non-suppressors, P=0.04; Figure 4). No significant differences
were seen between the groups in either the expression of other
cytokines in CD4+ T cells or in any CD8+ T cell populations.
Discussion
In ACTG A5197, vaccination with a rAd5 HIV-1 gag
therapeutic vaccine was associated with increased HIV-specific
T-cell activation and a trend towards improved virologic control
during the analytic treatment interruption. In this follow-up study,
we describe 11 subjects with viral load set point under 3.0 log10
copies/ml including 9 subjects who received the vaccine. No
virologic differences were identified in participants with and
without initial virologic suppression, but those with initial virologic
suppression were found to have a lower proportion of CD4+ T
cells expressing CTLA-4 prior to treatment interruption, and a
greater proportion of HIV-1 Gag-reactive CD4+ TNF-a+ cells
expressing either CTLA-4 or PD-1. Viral suppression, however,
was not sustained in the majority of subjects with initial virologic
control.
Participants with initial virologic suppression were found to
have an initial immunologic benefit whereas non-suppressors had
substantial CD4+ cell declines over the initial 16 weeks of the
analytic treatment interruption. However, this initial viral control
was not sustained in the majority of initial suppressors and was
associated with a CD4+ cell decline over the subsequent 33 weeks.
Potential explanations for the loss of viral control include the
waning of vaccine-induced immune function over time (cellular
immune responses were only evaluated early in the ATI) and
differing characteristics (e.g. size, heterogeneity) of the latent HIV-
1 reservoir from which the rebounding virus originated. Although
we detected no significant differences between initial virologic
suppressors and non-suppressors in the number of accumulated
HLA-associated HIV-1 polymorphisms, we cannot rule-out the
possibility that qualitative differences exist between escape
mutations with differential impact on viral fitness.
Three participants were able to maintain virologic suppression
49 weeks after treatment interruption. All three individuals had
received study vaccine and two of the three had CD4+ cell counts
at ATI week 49 above that found at study entry. In evaluating
which virologic or immunologic characteristics may be predictive
of initial virologic suppression, we found a trend toward lower pre-
ART viral load for participants with initial virologic suppression.
Pre-ART viral load has also been seen in other studies to be
associated with the extent of viral rebound [17–19] and validates
the use of stratification by viral load at randomization in A5197.
Two of the three participants who maintained virologic suppres-
sion were also found to have protective HLA alleles. HLA class I
molecules mediate the cell-mediated immune response to HIV and
play a crucial role in the immune control of HIV. Certain HLA
alleles, termed ‘‘protective’’, have been associated with decreased
viral load set point [20–23] and delayed disease progression [24].
In addition, in the STEP trial of the rAd5 Gag-Pol-Nef vaccine,
participants in the vaccine arm with protective HLA alleles were
found to have significantly lower viral load set point after infection
[25]. However, the impact of HLA alleles on initial virologic
rebound during treatment interruption is far less clear. In this
study, the prevalence of individuals with protective HLA alleles
was no higher in the initial suppressor group as compared to the
non-suppressor group (27% vs. 36%). One explanation is that in
these chronically infected individuals, HIV has had an opportunity
to adapt to the host immune response as evidenced by the fact that
almost all individuals in the study were found to have accumulated
HLA-associated polymorphisms in HIV-1 Gag.
The magnitude of HIV-1 Gag-specific IFN-c-producing CD4+
T cells has been previously associated with virologic control [26–
28]. It has been hoped that a therapeutic vaccine-induced
augmentation of such a response would lead to improved viral
control. However, in a recent study of a recombinant canarypox
HIV-1 vaccine (vCP1452), patients exposed to the vaccine had a
worse outcome including higher levels of viral replication [29]. A
subsequent analysis suggested that the extent of vaccine-induced
activation of HIV-specific CD4+ T cells was associated with the
detrimental outcome [30]. In contrast, we found no evidence of an
adverse effect of HIV-specific CD4+ T-cell activation on plasma
viremia. In addition, the initial analysis of A5197 found that a
greater number of gag-specific IFN-c-producing CD4+ T cells
were associated with lower viral rebound [6].
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CTLA-4 and PD-1 are inhibitory immunoregulatory molecules
that regulate T cell activation and peripheral immune tolerance
[31]. Their expression on HIV- specific CD4+ T cells has been
associated with increased viral load and disease progression
[32,33]. As might be expected, we found that CD4+ T cells from
initial virologic suppressors had a lower expression of CTLA-4
immediately prior to the ATI. We found, however, that CTLA-4+
and PD-1+ cells from initial virologic suppressors made up a
greater proportion of HIV-1 Gag-specific CD4+ TNF-a+ T cells
than those from non-suppressors. One potential explanation may be
that the subpopulation of CD4+ T cells expressing TNF-a and
CTLA-4 or PD-1 may be less readily able to support productive
HIV-1 infection despite evidence that CTLA-4 signaling may
be associated with increased CCR5 expression and enhanced
Figure 3. Expression of HIV-1 CD4+ T cells expressing either CTLA-4+ or PD-1+ by participants with and without initial virologic
suppression. Panel A, Percentage of CD4+ T cells expressing CTLA-4 at week 38 detected using flow cytometry. Panel B, Percentage of CD4+ T cells
expressing PD-1 at week 38 detected using flow cytometry.
doi:10.1371/journal.pone.0034134.g003
Figure 2. HIV-1 Gag-specific CD4+ IFN-c-producing T cells at weeks 8 and 38 categorized by initial virologic suppression and
treatment arm. Panel A, CD4+ IFN-c response 8 weeks after receiving the first vaccine dose. Number of cells quantified by the intracellular cytokine
staining assay in response to pooled HIV Gag peptides. Panel B, CD4+ IFN-c response 38 weeks after receiving the first vaccine dose and immediately
prior to initiating the analytic treatment interruption. Statistical comparison not provided for participants in the ‘‘Suppressors (Placebo)’’ group as
only two participants fell into this category.
doi:10.1371/journal.pone.0034134.g002
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susceptibility to infection [34]. An alternative explanation is that
these cells may serve to augment the immune suppression of viral
replication or may reflect a more active antiviral response in other
compartments such as lymphoid or mucosal tissue. Characterization
of these T cell subsets in other HIV-infected populations is needed to
investigate further the importance of this exploratory finding.
This post-hoc analysis has several limitations. Only a subset of
participants were initial virologic suppressors, which limited our
ability to identify significant viral and immunologic predictors of
virologic control. The analysis of viral load and CD4+ cell counts
between ATI weeks 16 and 49 may be confounded by selection
bias, especially in the non-suppressor group. After the ATI week
16 time point, participants had the option of restarting ART and
those with particularly high viral loads or low CD4+ cell counts
were encouraged to do so. Therefore, the viral load increases and
CD4+ cell declines in the non-suppressor group are likely to be
underestimated, which may have obscured continued viral load
and CD4+ T cell benefits in the initial suppressor group.
Immunologic studies on the magnitude of CTLA-4 and PD-1
expression of CD4+ cells were performed on a subset of
participants, which may have limited our ability to detect a
significant difference between groups.
An effective HIV-1 therapeutic vaccine would be a significant
advance in our efforts at HIV eradication and could provide insight
into the optimal preventative vaccine strategy. In ACTG A5197, we
found that participants with initial virologic suppression had a lower
proportion of CD4+ T cells expressing CTLA-4 and a higher
percentage of Gag-specific CD4+ TNF-a+ cells expressing either
CTLA-4 or PD-1. Further studies are needed to determine whether
optimizing CTLA-4 and PD-1 expression on CD4+ T cells will
improve virologic control in recipients of other therapeutic vaccines
in development.
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